Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2018 16:00 ET | Source: TESARO, Inc.

Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer

Efficacy of niraparib in combination with an anti-PD-1 mAb surpasses historical efficacy benchmarks for PD-1 or PARP monotherapies in difficult-to-treat types of ovarian cancer, regardless of...
March 13, 2017 11:10 ET | Source: TESARO, Inc.

Tesaro Announces Presentation of Niraparib Phase 3 ENGOT-OV16/NOVA Trial Secondary Endpoint Results During SGO

NATIONAL HARBOR, Md., March 13, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of secondary endpoint results...